Mechanisms behind the high mortality rate in chronic Chagas cardiomyopathy: Unmasking a three-headed monster.
Chronic Chagas cardiomyopathy
Heart failure
Mortality
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
26 Sep 2024
26 Sep 2024
Historique:
revised:
16
08
2024
received:
19
06
2024
accepted:
22
08
2024
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
27
9
2024
Statut:
aheadofprint
Résumé
Chagas disease is a neglected tropical disease caused by the parasite Trypanosoma cruzi. Chronic Chagas cardiomyopathy (CCC), the most severe form of target organ involvement in Chagas disease, is characterized by a complex pathophysiology and a unique phenotype that differentiates it from other cardiomyopathies, highlighting its worse prognosis compared to other aetiologies of heart failure. The three pathophysiological mechanisms with the largest impact on this differential mortality include rapidly progressive heart failure, a high incidence of stroke, and a high burden of ventricular arrhythmias. However, despite significant advances in understanding the unique molecular circuits underlying these mechanisms, the new knowledge acquired has not been efficiently translated into specific diagnostic and therapeutic approaches for this unique cardiomyopathy. The lack of dedicated clinical trials and the limited CCC-specific risk stratification tools available are evidence of this reality. This review aims to provide an updated perspective of the evidence and pathophysiological mechanisms associated with the higher mortality observed in CCC compared to other cardiomyopathies and highlight opportunities in the diagnostic and therapeutic approaches of the disease.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Echeverría LE, Marcus R, Novick G, Sosa‐Estani S, Ralston K, Zaidel EJ, et al. WHF IASC roadmap on Chagas disease. Glob Heart 2020;15:26. https://doi.org/10.5334/gh.484
Rassi A, Rassi A, Marcondes De Rezende J. American trypanosomiasis (Chagas disease). Infect Dis Clin North Am 2012;26:275–291. https://doi.org/10.1016/j.idc.2012.03.002
Nadruz W, Gioli‐Pereira L, Bernardez‐Pereira S, Marcondes‐Braga FG, Fernandes‐Silva MM, Silvestre OM, et al. Temporal trends in the contribution of Chagas cardiomyopathy to mortality among patients with heart failure. Heart 2018;104:1522–1528. https://doi.org/10.1136/heartjnl‐2017‐312869
Echeverría LE, Saldarriaga C, Rivera‐Toquica AA, Gómez‐Ochoa SA, Cadena‐Bonfanti AJ, Zarama‐Márquez MH, et al.; RECOLFACA Investigators. Characterization of patients with heart failure of Chagas etiology in Colombia: An analysis based on the Colombian Registry of Heart Failure (RECOLFACA). Curr Probl Cardiol 2023;48:101964. https://doi.org/10.1016/j.cpcardiol.2023.101964
Vieira De Melo RM, De Azevedo DFC, Lira YM, Cardoso De Oliveira NF, Passos LCS. Chagas disease is associated with a worse prognosis at 1‐year follow‐up after implantable cardioverter‐defibrillator for secondary prevention in heart failure patients. Cardiovasc Electrophysiol 2019;30:2448–2452. https://doi.org/10.1111/jce.14164
Gómez‐Ochoa SA, Serrano‐García AY, Hurtado‐Ortiz A, Aceros A, Rojas LZ, Echeverría LE. A systematic review and meta‐analysis of mortality in chronic Chagas cardiomyopathy versus other cardiomyopathies: Higher risk or fiction? Rev Esp Cardiol (Engl Ed) 2024. https://doi.org/10.1016/j.rec.2024.02.014. In Press.
Shen L, Ramires F, Martinez F, Bodanese LC, Echeverría LE, Gómez EA, et al.; PARADIGM‐HF and ATMOSPHERE Investigators and Committees. Contemporary characteristics and outcomes in Chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy. Circ Heart Fail 2017;10:e004361. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004361
Díaz ML, Burgess K, Burchmore R, Gómez MA, Gómez‐Ochoa SA, Echeverría LE, et al. Metabolomic profiling of end‐stage heart failure secondary to chronic Chagas cardiomyopathy. Int J Mol Sci 2022;23:10456. https://doi.org/10.3390/ijms231810456
Echeverría LE, Rojas LZ, Gómez‐Ochoa SA, Rueda‐Ochoa OL, Sosa‐Vesga CD, Muka T, et al. Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy. PLoS One 2021;16:e0258622. https://doi.org/10.1371/journal.pone.0258622
Montalvo‐Ocotoxtle IG, Rojas‐Velasco G, Rodríguez‐Morales O, Arce‐Fonseca M, Baeza‐Herrera LA, Arzate‐Ramírez A, et al. Chagas heart disease: Beyond a single complication, from asymptomatic disease to heart failure. J Clin Med 2022;11:7262. https://doi.org/10.3390/jcm11247262
Chadalawada S, Rassi A, Samara O, Monzon A, Gudapati D, Vargas Barahona L, et al. Mortality risk in chronic Chagas cardiomyopathy: A systematic review and meta‐analysis. ESC Heart Fail 2021;8:5466–5481. https://doi.org/10.1002/ehf2.13648
Medina‐Rincón GJ, Gallo‐Bernal S, Jiménez PA, Cruz‐Saavedra L, Ramírez JD, Rodríguez MJ, et al. Molecular and clinical aspects of chronic manifestations in Chagas disease: A state‐of‐the‐art review. Pathogens 2021;10:1493. https://doi.org/10.3390/pathogens10111493
Gómez‐Ochoa SA, Rojas LZ, Echeverría LE, Muka T, Franco OH. Global, regional, and national trends of Chagas disease from 1990 to 2019: Comprehensive analysis of the Global Burden of Disease Study. Glob Heart 2022;17:59. https://doi.org/10.5334/gh.1150
Institute for Health Metrics and Evaluation (IHME). Epi Visualization. Seattle, WA: IHME, University of Washington. 2024 http://vizhub.healthdata.org/epi) (Accessed 16 July 2024)
Requena‐Méndez A, Aldasoro E, de Lazzari E, Sicuri E, Brown M, Moore DAJ, et al. Prevalence of Chagas disease in Latin‐American migrants living in Europe: A systematic review and meta‐analysis. PLoS Negl Trop Dis 2015;9:e0003540. https://doi.org/10.1371/journal.pntd.0003540
Navarro M, Reguero L, Subirà C, Blázquez‐Pérez A, Requena‐Méndez A. Estimating Chagas disease prevalence and number of underdiagnosed, and undertreated individuals in Spain. Travel Med Infect Dis 2022;47:102284. https://doi.org/10.1016/j.tmaid.2022.102284
González Sanz M, De Sario V, García‐Mingo A, Nolder D, Dawood N, Álvarez‐Martínez MJ, et al. Chagas disease in the United Kingdom: A review of cases at the Hospital for Tropical Diseases London 1995–2018. The current state of detection of Chagas disease in the UK. Travel Med Infect Dis 2020;36:101760. https://doi.org/10.1016/j.tmaid.2020.101760
Strasen J, Williams T, Ertl G, Zoller T, Stich A, Ritter O. Epidemiology of Chagas disease in Europe: Many calculations, little knowledge. Clin Res Cardiol 2014;103:1–10. https://doi.org/10.1007/s00392‐013‐0613‐y
Gonzalez‐Sanz M, Crespillo‐Andújar C, Chamorro‐Tojeiro S, Monge‐Maillo B, Perez‐Molina JA, Norman FF. Chagas disease in Europe. Trop Med Infect Dis 2023;8:513. https://doi.org/10.3390/tropicalmed8120513
Kemmerling U, Osuna A, Schijman AG, Truyens C. Congenital transmission of Trypanosoma cruzi: A review about the interactions between the parasite, the placenta, the maternal and the fetal/neonatal immune responses. Front Microbiol 2019;10:1854. https://doi.org/10.3389/fmicb.2019.01854
Colombo V, Giacomelli A, Casazza G, Galimberti L, Bonazzetti C, Sabaini F, et al. Trypanosoma cruzi infection in Latin American pregnant women living outside endemic countries and frequency of congenital transmission: A systematic review and meta‐analysis. J Travel Med 2021;28:taaa170. https://doi.org/10.1093/jtm/taaa170
Assal A, Corbi C. Chagas disease and blood transfusion: an emerging issue in non‐endemic countries. Transfus Clin Biol 2011;18:286–291. https://doi.org/10.1016/j.tracli.2011.02.006
Kitchen AD, Hewitt PE, Chiodini PL. The early implementation of Trypanosoma cruzi antibody screening of donors and donations within England: Preempting a problem. Transfusion 2012;52:1931–1939. https://doi.org/10.1111/j.1537‐2995.2012.03599.x
Grupo de Trabajo Donación de Sangre e Inmigración MdSyPS. Enfermedad de Chagas y Donacion de Sangre. 2009. https://www.sanidad.gob.es/profesionales/saludPublica/medicinaTransfusional/publicaciones/docs/informeChagasJulio09.pdf (Accessed 16 August 2024).
Freitas HFG, Chizzola PR, Paes ÂT, Lima ACP, Mansur AJ. Risk stratification in a Brazilian hospital‐based cohort of 1220 outpatients with heart failure: Role of Chagas' heart disease. Int J Cardiol 2005;102:239–247. https://doi.org/10.1016/j.ijcard.2004.05.025
Bonney KM, Luthringer DJ, Kim SA, Garg NJ, Engman DM. Pathology and pathogenesis of Chagas heart disease. Annu Rev Pathol 2019;14:421–447. https://doi.org/10.1146/annurev‐pathol‐020117‐043711
Fernandes MC, Andrews NW. Host cell invasion by Trypanosoma cruzi: A unique strategy that promotes persistence. FEMS Microbiol Rev 2012;36:734–747. https://doi.org/10.1111/j.1574‐6976.2012.00333.x
Andrade ZA. Immunopathology of Chagas disease. Mem Inst Oswaldo Cruz 1999;94:71–80. https://doi.org/10.1590/s0074‐02761999000700007
Díaz ML, Delgado FA, Martínez RA, Jaimes MA, Echeverría LE, Gómez‐Ochoa SA, et al. The characterization of cardiac explants reveals unique fibrosis patterns and a predominance of CD8+ T cell subpopulations in patients with chronic Chagas cardiomyopathy. Pathogens 2022;11:1402. https://doi.org/10.3390/pathogens11121402
Martin D, Tarleton R. Generation, specificity, and function of CD8+ T cells in Trypanosoma cruzi infection. Immunol Rev 2004;201:304–317. https://doi.org/10.1111/j.0105‐2896.2004.00183.x
Gomes JAS, Bahia‐Oliveira LMG, Rocha MOC, Martins‐Filho OA, Gazzinelli G, Correa‐Oliveira R. Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1‐specific immune response. Infect Immun 2003;71:1185–1193. https://doi.org/10.1128/IAI.71.3.1185‐1193.2003
Tanaka DM, Simões MV, Marin‐Neto JA. Coronary microvascular dysfunction due to Chagas disease: Where are we now? Expert Rev Cardiovasc Ther 2023;21:379–387. https://doi.org/10.1080/14779072.2023.2215983
de Brito ASX, Moll‐Bernardes RJ, Pinheiro MVT, Camargo GC, Siqueira FPR, Oliveira RS, et al. Autonomic denervation, myocardial hypoperfusion and fibrosis may predict ventricular arrhythmia in the early stages of Chagas cardiomyopathy. J Nucl Cardiol 2023;30:2379–2388. https://doi.org/10.1007/s12350‐023‐03281‐9
Barizon GC, Simões MV, Schmidt A, Gadioli LP, Murta Junior LO. Relationship between microvascular changes, autonomic denervation, and myocardial fibrosis in Chagas cardiomyopathy: Evaluation by MRI and SPECT imaging. J Nucl Cardiol 2020;27:434–444. https://doi.org/10.1007/s12350‐018‐1290‐z
de Carvalho AC, Tanowitz HB, Wittner M, Dermietzel R, Roy C, Hertzberg EL, et al. Gap junction distribution is altered between cardiac myocytes infected with Trypanosoma cruzi. Circ Res 1992;70:733–742. https://doi.org/10.1161/01.res.70.4.733
Marin‐Neto JA, Cunha‐Neto E, Maciel BC, Simões MV. Pathogenesis of chronic Chagas heart disease. Circulation 2007;115:1109–1123. https://doi.org/10.1161/CIRCULATIONAHA.106.624296
Nunes MCP, Beaton A, Acquatella H, Bern C, Bolger AF, Echeverría LE, et al.; American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Stroke Council. Chagas cardiomyopathy: An update of current clinical knowledge and management: A scientific statement from the American Heart Association. Circulation 2018;138:e169–e209. https://doi.org/10.1161/CIR.0000000000000599
Chaves AT, Menezes CAS, Costa HS, Nunes MCP, Rocha MOC. Myocardial fibrosis in Chagas disease and molecules related to fibrosis. Parasite Immunol 2019;41:e12663. https://doi.org/10.1111/pim.12663
Senra T, Ianni BM, Costa ACP, Mady C, Martinelli‐Filho M, Kalil‐Filho R, et al. Long‐term prognostic value of myocardial fibrosis in patients with Chagas cardiomyopathy. J Am Coll Cardiol 2018;72:2577–2587. https://doi.org/10.1016/j.jacc.2018.08.2195
Marin‐Neto JA, Rassi A Jr, Oliveira GMM, Correia LCL, Ramos AN Jr, Luquetti, et al. SBC guideline on the diagnosis and treatment of patients with cardiomyopathy of Chagas disease – 2023. Arq Bras Cardiol 2023;120:e20230269. https://doi.org/10.36660/abc.20230269
Chen LS, Zhou S, Fishbein MC, Chen P‐S. New perspectives on the role of autonomic nervous system in the genesis of arrhythmias. J Cardiovasc Electrophysiol 2007;18:123–127. https://doi.org/10.1111/j.1540‐8167.2006.00590.x
Machado CR, Machado AB, Chiari CA. Recovery from heart norepinephrine depletion in experimental Chagas' disease. Am J Trop Med Hyg 1978;27:20–24. https://doi.org/10.4269/ajtmh.1978.27.20
Santos‐Miranda A, Joviano‐Santos JV, Sarmento JO, Costa AD, Soares ATC, Machado FS, et al. A novel substrate for arrhythmias in Chagas disease. PLoS Negl Trop Dis 2021;15:e0009421. https://doi.org/10.1371/journal.pntd.0009421
Lerman BB, Markowitz SM, Cheung JW, Thomas G, Ip JE. Ventricular tachycardia due to triggered activity: Role of early and delayed afterdepolarizations. JACC Clin Electrophysiol 2024;10:379–401. https://doi.org/10.1016/j.jacep.2023.10.033
Ribeiro Cury Pavão ML, Arfelli E, Scorzoni‐Filho A, Pavão RB, Pazin‐Filho A, Marin‐Neto JA, et al. Electrical storm in Chagas cardiomyopathy: Clinical predictors, outcome, and arrhythmic characteristics in a prospective registry. JACC Clin Electrophysiol 2020;6:1238–1245. https://doi.org/10.1016/j.jacep.2020.04.028
Barros ML, Ribeiro A, do Carmo Nunes M, da Costa Rocha MO. Association between left ventricular wall motion abnormalities and ventricular arrhythmia in the indeterminate form of Chagas disease. Rev Soc Bras Med Trop 2011; 44: 213–216. https://doi.org/10.1590/s0037‐86822011005000020
Rojas LZ, Glisic M, Pletsch‐Borba L, Echeverría LE, Bramer WM, Bano A, et al. Electrocardiographic abnormalities in Chagas disease in the general population: A systematic review and meta‐analysis. PLoS Negl Trop Dis 2018;12:e0006567. https://doi.org/10.1371/journal.pntd.0006567
de Paola AA, Gomes JA, Terzian AB, Miyamoto MH, Martinez Fo EE. Ventricular tachycardia during exercise testing as a predictor of sudden death in patients with chronic Chagasic cardiomyopathy and ventricular arrhythmias. Br Heart J 1995;74:293–295. https://doi.org/10.1136/hrt.74.3.293
Rassi A, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: A systematic review of observational studies. Circulation 2007;115:1101–1108. https://doi.org/10.1161/CIRCULATIONAHA.106.627265
Azevedo ACA, Barros MVL, Klaboe LG, Edvardsen T, Costa HS, Paixao GMM, et al. Association between myocardial mechanical dispersion and ventricular arrhythmogenicity in Chagas cardiomyopathy. Int J Cardiovasc Imaging 2021;37:2727–2734. https://doi.org/10.1007/s10554‐021‐02246‐8
Pinheiro MVT, Moll‐Bernardes RJ, Camargo GC, Siqueira FP, de Azevedo CF, Holanda MT Mendes FSNS, Sangenis LHC, Mediano MFF, Sousa AS Associations between cardiac magnetic resonance T1 mapping parameters and ventricular arrhythmia in patients with Chagas disease. Am J Trop Med Hyg 2020; 103: 745–751. https://doi.org/10.4269/ajtmh.20‐0122
Gómez‐Ochoa SA, Rojas LZ, Hernández‐Vargas JA, Trujillo‐Cáceres SJ, Hurtado‐Ortiz A, Licht‐Ardila M, et al. Myocardial fibrosis by magnetic resonance and outcomes in Chagas disease: A systematic review and meta‐analysis. JACC Cardiovasc Imaging 2024;17:552–555. https://doi.org/10.1016/j.jcmg.2023.11.003
Cerqueira‐Silva T, Gonçalves BM, Pereira CB, Porto LM, Marques ME, Santos LS, et al. Chagas disease is an independent predictor of stroke and death in a cohort of heart failure patients. Int J Stroke 2022;17:180–188. https://doi.org/10.1177/17474930211006284
Carod‐Artal FJ, Vargas AP, Horan TA, Nunes LGN. Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease. Stroke 2005;36:965–970. https://doi.org/10.1161/01.STR.0000163104.92943.50
Paixão LC, Ribeiro AL, Valacio RA, Teixeira AL. Chagas disease: Independent risk factor for stroke. Stroke 2009;40:3691–3694. https://doi.org/10.1161/STROKEAHA.109.560854
Cardoso RN, Macedo FYB, Garcia MN, Garcia DC, Benjo AM, Aguilar D, et al. Chagas cardiomyopathy is associated with higher incidence of stroke: A meta‐analysis of observational studies. J Card Fail 2014;20:931–938. https://doi.org/10.1016/j.cardfail.2014.09.003
de Macedo IS, Dinardi LFL, Pereira TV, de Almeida LKR, Barbosa TS, Benvenuti LA, et al. Thromboembolic findings in patients with heart failure at autopsy. Cardiovasc Pathol 2018;35:23–28. https://doi.org/10.1016/j.carpath.2018.04.004
Nunes MCP, Badano LP, Marin‐Neto JA, Edvardsen T, Fernández‐Golfín C, Bucciarelli‐Ducci C, et al. Multimodality imaging evaluation of Chagas disease: An expert consensus of Brazilian Cardiovascular Imaging Department (DIC) and the European Association of Cardiovascular Imaging (EACVI). Eur Heart J Cardiovasc Imaging 2018;19:459–460n. https://doi.org/10.1093/ehjci/jex154
Echeverría LE, Rojas LZ, Gómez‐Ochoa SA. Coagulation disorders in Chagas disease: A pathophysiological systematic review and meta‐analysis. Thromb Res 2021;201:73–83. https://doi.org/10.1016/j.thromres.2021.02.025
Cucunubá ZM, Okuwoga O, Basáñez M‐G, Nouvellet P. Increased mortality attributed to Chagas disease: A systematic review and meta‐analysis. Parasit Vectors 2016;9:42. https://doi.org/10.1186/s13071‐016‐1315‐x
Ruzza A, Czer LSC, Arabia F, Vespignani R, Esmailian F, Cheng W, et al. Left ventricular reconstruction for postinfarction left ventricular aneurysm: Review of surgical techniques. Tex Heart Inst J 2017;44:326–335. https://doi.org/10.14503/THIJ‐16‐6068
Eaton LW, Weiss JL, Bulkley BH, Garrison JB, Weisfeldt ML. Regional cardiac dilatation after acute myocardial infarction: Recognition by two‐dimensional echocardiography. N Engl J Med 1979;300:57–62. https://doi.org/10.1056/NEJM197901113000202
Nogueira EA, Ueti OM, Vieira WR. The apical ventricular lesion in Chagas' heart disease. Sao Paulo Med J 1995;113:785–790. https://doi.org/10.1590/s1516‐31801995000200008
Pino‐Marín A, Medina‐Rincón GJ, Gallo‐Bernal S, Duran‐Crane A, Arango Duque ÁI, Rodríguez MJ, et al. Chagas cardiomyopathy: From Romaña sign to heart failure and sudden cardiac death. Pathogens 2021;10:505. https://doi.org/10.3390/pathogens10050505
Cardoso R, Garcia D, Fernandes G, He L, Lichtenberger P, Viles‐Gonzalez J, et al. The prevalence of atrial fibrillation and conduction abnormalities in Chagas' disease: A meta‐analysis. J Cardiovasc Electrophysiol 2016;27:161–169. https://doi.org/10.1111/jce.12845
Herrera RN, Díaz E, Pérez R, Chaín S, Sant‐Yacumo R, Rodríguez E, et al. The prothrombotic state in early stages of chronic Chagas' disease. Rev Esp Cardiol 2003;56:377–382. https://doi.org/10.1016/s0300‐8932(03)76881‐x
Margetic S. Inflammation and haemostasis. Biochem Med (Zagreb) 2012;22:49–62. https://doi.org/10.11613/BM.2012.006
Davis RP, Miller‐Dorey S, Jenne CN. Platelets and coagulation in infection. Clin Transl Immunology 2016;5:e89. https://doi.org/10.1038/cti.2016.39
Pérez AR, Silva‐Barbosa SD, Berbert LR, Revelli S, Beloscar J, Savino W, et al. Immunoneuroendocrine alterations in patients with progressive forms of chronic Chagas disease. J Neuroimmunol 2011;235:84–90. https://doi.org/10.1016/j.jneuroim.2011.03.010
González FB, Villar SR, Pacini MF, Bottasso OA, Pérez AR. Immune‐neuroendocrine and metabolic disorders in human and experimental T. cruzi infection: New clues for understanding Chagas disease pathology. Biochim Biophys Acta Mol Basis Dis 2020;1866:165642. https://doi.org/10.1016/j.bbadis.2019.165642
Duarte‐Silva E, Maes M, Macedo D, Savino W, Peixoto CA. Shared neuroimmune and oxidative pathways underpinning Chagas disease and major depressive disorder. Transl Psychiatry 2020;10:419. https://doi.org/10.1038/s41398‐020‐01105‐9
Sheng JA, Bales NJ, Myers SA, Bautista AI, Roueinfar M, Hale TM, et al. The hypothalamic‐pituitary‐adrenal axis: Development, programming actions of hormones, and maternal‐fetal interactions. Front Behav Neurosci 2021;14:601939. https://doi.org/10.3389/fnbeh.2020.601939
Silverman MN, Pearce BD, Biron CA, Miller AH. Immune modulation of the hypothalamic‐pituitary‐adrenal (HPA) axis during viral infection. Viral Immunol 2005;18:41–78. https://doi.org/10.1089/vim.2005.18.41
Santos CD, Toldo MPA, Santello FH, Del Vecchio Filipin M, Brazão V, JC do Prado Jr. Dehydroepiandrosterone increases resistance to experimental infection by Trypanosoma cruzi. Vet Parasitol 2008; 153: 238–243. https://doi.org/10.1016/j.vetpar.2008.01.039
Santos CD, Toldo MPA, Levy AMA, Kawasse LM, Zucoloto S, do Prado JC. Dehydroepiandrosterone affects Trypanosoma cruzi tissue parasite burdens in rats. Acta Trop 2007;102:143–150. https://doi.org/10.1016/j.actatropica.2007.04.010
Rojas LZ, Gómez‐Ochoa SA, Echeverría LE, Bautista‐Niño PK, Hunziker L, Eisenga MF, et al. Circulating DHEA‐S levels and major cardiovascular outcomes in chronic Chagas cardiomyopathy: A prospective cohort study. Int J Cardiol 2022;349:90–95. https://doi.org/10.1016/j.ijcard.2021.11.054
Echeverría LE, Rojas LZ, López LA, Rueda‐Ochoa OL, Gómez‐Ochoa SA, Morillo CA. Myocardial involvement in Chagas disease and insulin resistance: A non‐metabolic model of cardiomyopathy. Glob Heart 2020;15:36. https://doi.org/10.5334/gh.793
Xavier IGG, Vieira MC, Rodrigues Junior LF, Sperandio da Silva GM, da Silva PS, de Holanda MT, et al. Prevalence of metabolic syndrome and associated factors among patients with chronic Chagas disease. PLoS One 2021;16:e0249116. https://doi.org/10.1371/journal.pone.0249116
González F, Villar S, D'Attilio L, Leiva R, Marquez J, Lioi S, et al. Dysregulated network of immune, endocrine and metabolic markers is associated to more severe human chronic Chagas cardiomyopathy. Neuroimmunomodulation 2018;25:119–128. https://doi.org/10.1159/000491699
Barbosa‐Ferreira JM, Mady C, Ianni BM, Lopes HF, Ramires FJA, Salemi VMC, et al. Dysregulation of autonomic nervous system in Chagas' heart disease is associated with altered adipocytokines levels. PLoS One 2015;10:e0131447. https://doi.org/10.1371/journal.pone.0131447
Elendu C, Amaechi DC, Elendu TC, Ashna M, Ross‐Comptis J, Ansong SO, et al. Heart failure and diabetes: Understanding the bidirectional relationship. Medicine (Baltimore) 2023;102:e34906. https://doi.org/10.1097/MD.0000000000034906
Morillo CA, Marin‐Neto JA, Avezum A, Sosa‐Estani S, Rassi A, Rosas F, et al.; BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. N Engl J Med 2015;373:1295–1306. https://doi.org/10.1056/NEJMoa1507574
Lopes RD, Gimpelewicz C, McMurray JJV. Chagas disease: Still a neglected emergency? Lancet 2020;395:1113–1114. https://doi.org/10.1016/S0140‐6736(20)30171‐9
de Souza Santos E, Silva DKC, BPZC Dos Reis, Barreto BC, Cardoso CMA, RR Dos Santos, et al. Immunomodulation for the treatment of chronic Chagas disease cardiomyopathy: A new approach to an old enemy. Front Cell Infect Microbiol 2021;11:765879. https://doi.org/10.3389/fcimb.2021.765879
Macambira SG, Vasconcelos JF, Costa CRS, Klein W, Lima RS, Guimarães P, et al. Granulocyte colony‐stimulating factor treatment in chronic Chagas disease: Preservation and improvement of cardiac structure and function. FASEB J 2009;23:3843–3850. https://doi.org/10.1096/fj.09‐137869
Vasconcelos JF, Souza BSF, Lins TFS, Garcia LMS, Kaneto CM, Sampaio GP, et al. Administration of granulocyte colony‐stimulating factor induces immunomodulation, recruitment of T regulatory cells, reduction of myocarditis and decrease of parasite load in a mouse model of chronic Chagas disease cardiomyopathy. FASEB J 2013;27:4691–4702. https://doi.org/10.1096/fj.13‐229351
Pereira IR, Vilar‐Pereira G, Moreira OC, Ramos IP, Gibaldi D, Britto C, et al. Pentoxifylline reverses chronic experimental Chagasic cardiomyopathy in association with repositioning of abnormal CD8+ T‐cell response. PLoS Negl Trop Dis 2015;9:e0003659. https://doi.org/10.1371/journal.pntd.0003659
Vilar‐Pereira G, Resende Pereira I, de Souza Ruivo LA, Cruz Moreira O, da Silva AA, Britto C, et al. Combination chemotherapy with suboptimal doses of benznidazole and pentoxifylline sustains partial reversion of experimental Chagas' heart disease. Antimicrob Agents Chemother 2016;60:4297–4309. https://doi.org/10.1128/AAC.02123‐15
González‐Herrera F, Cramer A, Pimentel P, Castillo C, Liempi A, Kemmerling U, et al. Simvastatin attenuates endothelial activation through 15‐epi‐lipoxin A4 production in murine chronic Chagas cardiomyopathy. Antimicrob Agents Chemother 2017;61:e02137‐16. https://doi.org/10.1128/AAC.02137‐16
Soares MBP, Lima RS, Rocha LL, Takyia CM, Pontes‐de‐Carvalho L, de Carvalho ACC, et al. Transplanted bone marrow cells repair heart tissue and reduce myocarditis in chronic Chagasic mice. Am J Pathol 2004;164:441–447. https://doi.org/10.1016/s0002‐9440(10)63134‐3
Goldenberg RCS, Jelicks LA, Fortes FSA, Weiss LM, Rocha LL, Zhao D, et al. Bone marrow cell therapy ameliorates and reverses Chagasic cardiomyopathy in a mouse model. J Infect Dis 2008;197:544–547. https://doi.org/10.1086/526793
Jasmin J, Jelicks LA, Koba W, Tanowitz HB, Mendez‐Otero R, Campos de Carvalho AC, et al. Mesenchymal bone marrow cell therapy in a mouse model of chagas disease. Where do the cells go? PLoS Negl Trop Dis 2012;6:e1971. https://doi.org/10.1371/journal.pntd.0001971
Mello DB, Ramos IP, Mesquita FCP, Brasil GV, Rocha NN, Takiya CM, et al. Adipose tissue‐derived mesenchymal stromal cells protect mice infected with Trypanosoma cruzi from cardiac damage through modulation of anti‐parasite immunity. PLoS Negl Trop Dis 2015;9:e0003945. https://doi.org/10.1371/journal.pntd.0003945
Silva DN, Souza BSF, Vasconcelos JF, Azevedo CM, Valim CXR, Paredes BD, et al. Granulocyte‐colony stimulating factor‐overexpressing mesenchymal stem cells exhibit enhanced immunomodulatory actions through the recruitment of suppressor cells in experimental Chagas disease cardiomyopathy. Front Immunol 2018;9:1449. https://doi.org/10.3389/fimmu.2018.01449
de Souza Santos E, de Aragão‐França LS, Meira CS, Cerqueira JV, Vasconcelos JF, Nonaka CKV, et al. Tolerogenic dendritic cells reduce cardiac inflammation and fibrosis in chronic Chagas disease. Front Immunol 2020; 11:488. https://doi.org/10.3389/fimmu.2020.00488
Waghabi MC, Ferreira RR, da Silva Abreu R, Degrave W, de Souza EM, Bailly S, et al. Transforming growth factor‐ß as a therapeutic target for the cardiac damage of Chagas disease. Mem Inst Oswaldo Cruz 2022; 117: e210395. https://doi.org/10.1590/0074‐02760210395
Ferreira RR, de Souza EM, Vilar‐Pereira G, Degrave WMS, da Silva Abreu R, Meuser‐Batista M, et al. In Chagas disease, transforming growth factor beta neutralization reduces Trypanosoma cruzi infection and improves cardiac performance. Front Cell Infect Microbiol 2022;12: 1017040. https://doi.org/10.3389/fcimb.2022.1017040
Waghabi MC, Keramidas M, Calvet CM, Meuser M, de Nazaré C, Soeiro M, et al. SB‐431542, a transforming growth factor beta inhibitor, impairs Trypanosoma cruzi infection in cardiomyocytes and parasite cycle completion. Antimicrob Agents Chemother 2007;51:2905–2910. https://doi.org/10.1128/AAC.00022‐07
Waghabi MC, de Souza EM, de Oliveira GM, Keramidas M, Feige JJ, Araújo‐Jorge TC, et al. Pharmacological inhibition of transforming growth factor beta signaling decreases infection and prevents heart damage in acute Chagas' disease. Antimicrob Agents Chemother 2009;53:4694–4701. https://doi.org/10.1128/AAC.00580‐09
Araújo‐Jorge TC, Waghabi MC, Bailly S, Feige J‐J. The TGF‐β pathway as an emerging target for Chagas disease therapy. Clin Pharmacol Ther 2012;92:613–621. https://doi.org/10.1038/clpt.2012.102
Shi N, Wang Z, Zhu H, Liu W, Zhao M, Jiang X, et al. Research progress on drugs targeting the TGF‐β signaling pathway in fibrotic diseases. Immunol Res 2022;70:276–288. https://doi.org/10.1007/s12026‐022‐09267‐y
de Sousa AS, Xavier SS, de Freitas GR, Hasslocher‐Moreno A. Prevention strategies of cardioembolic ischemic stroke in Chagas' disease. Arq Bras Cardiol 2008;91:306–310. https://doi.org/10.1590/s0066‐782x2008001700004
Roberti R, Iannone LF, Palleria C, Curcio A, Rossi M, Sciacqua A, et al. Direct oral anticoagulants: From randomized clinical trials to real‐world clinical practice. Front Pharmacol 2021;12:684638. https://doi.org/10.3389/fphar.2021.684638
Serenelli M, Pavasini R, Vitali F, Tonet E, Cantone A, Di Ienno L, et al. Direct oral anticoagulants for the treatment of left ventricular thrombosis: An updated systematic review and meta‐analysis. J Cardiovasc Med (Hagerstown) 2022;23:672–677. https://doi.org/10.2459/JCM.0000000000001368
Las Casas AA, Las Casas AA, Borges MAF, Melo‐Souza SE. Rivaroxaban for treatment of intraventricular thrombus in Chagas disease. J Cardiol Cases 2015;13:75–77. https://doi.org/10.1016/j.jccase.2015.10.010
Bennett S, Satchithananda D, Law G. The use of apixaban for the treatment of an LV thrombus. Echo Res Pract 2018;5:K63–K66. https://doi.org/10.1530/ERP‐18‐0036
Piccini JP, Berger JS, O'Connor CM. Amiodarone for the prevention of sudden cardiac death: A meta‐analysis of randomized controlled trials. Eur Heart J 2009;30:1245–1253. https://doi.org/10.1093/eurheartj/ehp100
Stein C, Migliavaca CB, Colpani V, da Rosa PR, Sganzerla D, Giordani NE, et al. Amiodarone for arrhythmia in patients with Chagas disease: A systematic review and individual patient data meta‐analysis. PLoS Negl Trop Dis 2018;12:e0006742. https://doi.org/10.1371/journal.pntd.0006742
Al‐Gobari M, El Khatib C, Pillon F, Gueyffier F. β‐Blockers for the prevention of sudden cardiac death in heart failure patients: A meta‐analysis of randomized controlled trials. BMC Cardiovasc Disord 2013;13:52. https://doi.org/10.1186/1471‐2261‐13‐52
Issa VS, Amaral AF, Cruz FD, Ferreira SMA, Guimarães GV, Chizzola PR, et al. Beta‐blocker therapy and mortality of patients with Chagas cardiomyopathy: A subanalysis of the REMADHE prospective trial. Circ Heart Fail 2010;3:82–88. https://doi.org/10.1161/CIRCHEARTFAILURE.109.882035
Rassi FM, Minohara L, Rassi A, Correia LCL, Marin‐Neto JA, Rassi A, et al. Systematic review and meta‐analysis of clinical outcome after implantable cardioverter‐defibrillator therapy in patients with Chagas heart disease. JACC Clin Electrophysiol 2019;5:1213–1223. https://doi.org/10.1016/j.jacep.2019.07.003
Carmo AAL, de Sousa MR, Agudelo JF, Boersma E, Rocha MOC, Ribeiro ALP, et al. Implantable cardioverter‐defibrillator in Chagas heart disease: A systematic review and meta‐analysis of observational studies. Int J Cardiol 2018;267:88–93. https://doi.org/10.1016/j.ijcard.2018.05.091
Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008;359:1009–1017. https://doi.org/10.1056/NEJMoa071098
Pisani CF, Romero J, Lara S, Hardy C, Chokr M, Sacilotto L, et al. Efficacy and safety of combined endocardial/epicardial catheter ablation for ventricular tachycardia in Chagas disease: A randomized controlled study. Heart Rhythm 2020;17:1510–1518. https://doi.org/10.1016/j.hrthm.2020.02.009
Hadid C, Di Toro D, Celano L, Martinenghi N, Antezana‐Chaves E, Gallino S, et al. Catheter ablation of ventricular tachycardia in patients with electrical storm, with a special focus on patients with Chagas disease. J Interv Card Electrophysiol 2021;62:557–564. https://doi.org/10.1007/s10840‐020‐00915‐7
Henz BD, do Nascimento TA, de O Dietrich C, Dalegrave C, Hernandes V, Mesas CE, et al. Simultaneous epicardial and endocardial substrate mapping and radiofrequency catheter ablation as first‐line treatment for ventricular tachycardia and frequent ICD shocks in chronic Chagasic cardiomyopathy. J Interv Card Electrophysiol 2009; 26: 195–205. https://doi.org/10.1007/s10840‐009‐9433‐4
Hawson J, Harmer JA, Cowan M, Virk S, Campbell T, Bennett RG, et al. Renal denervation for the management of refractory ventricular arrhythmias: A systematic review. JACC Clin Electrophysiol 2021;7:100–108. https://doi.org/10.1016/j.jacep.2020.07.019
Spadaro AG, Bocchi EA, Souza GE, Filho AE, Mariani J, Campos CM, et al. Renal denervation in patients with heart failure secondary to Chagas' disease: A pilot randomized controlled trial. Catheter Cardiovasc Interv 2019;94:644–650. https://doi.org/10.1002/ccd.28393
de Campos Lopes CB, Yamada AT, Araújo F, Pereira Barreto AC, Mansur AJ. Socioeconomic factors in the prognosis of heart failure in a Brazilian cohort. Int J Cardiol 2006;113:181–187. https://doi.org/10.1016/j.ijcard.2005.11.009
Ferreira AM, Sabino ÉC, de Oliveira LC, Oliveira CDL, Cardoso CS, Ribeiro ALP, et al. Impact of the social context on the prognosis of Chagas disease patients: Multilevel analysis of a Brazilian cohort. PLoS Negl Trop Dis 2020;14:e0008399. https://doi.org/10.1371/journal.pntd.0008399